Effects of chronic naltrexone treatment on relapse-related behavior and neural responses to fentanyl in awake nonhuman primates.

Autor: Withey SL; Behavioral Biology Program, McLean Hospital/Harvard Medical School, 115 Mill St., Belmont, MA, 02478, USA.; Department of Psychiatry, Harvard Medical School, Boston, MA, USA., Deshpande HU; Behavioral Biology Program, McLean Hospital/Harvard Medical School, 115 Mill St., Belmont, MA, 02478, USA.; Department of Psychiatry, Harvard Medical School, Boston, MA, USA.; Behavioral Neuroimaging Laboratory, McLean Hospital, Belmont, MA, USA., Cao L; Behavioral Biology Program, McLean Hospital/Harvard Medical School, 115 Mill St., Belmont, MA, 02478, USA.; Behavioral Neuroimaging Laboratory, McLean Hospital, Belmont, MA, USA., Bergman J; Behavioral Biology Program, McLean Hospital/Harvard Medical School, 115 Mill St., Belmont, MA, 02478, USA.; Department of Psychiatry, Harvard Medical School, Boston, MA, USA., Kohut SJ; Behavioral Biology Program, McLean Hospital/Harvard Medical School, 115 Mill St., Belmont, MA, 02478, USA. skohut@mclean.harvard.edu.; Department of Psychiatry, Harvard Medical School, Boston, MA, USA. skohut@mclean.harvard.edu.; Behavioral Neuroimaging Laboratory, McLean Hospital, Belmont, MA, USA. skohut@mclean.harvard.edu.; McLean Imaging Center, McLean Hospital, Belmont, MA, USA. skohut@mclean.harvard.edu.
Jazyk: angličtina
Zdroj: Psychopharmacology [Psychopharmacology (Berl)] 2024 Nov; Vol. 241 (11), pp. 2289-2302. Date of Electronic Publication: 2024 Aug 10.
DOI: 10.1007/s00213-024-06633-6
Abstrakt: Naltrexone, an opioid antagonist that blocks the reinforcing properties of opioid agonists, is often prescribed to preclude relapse to opioid use disorder (OUD) following detoxification. However, few laboratory studies have directly investigated the ability of naltrexone to alter relapse-inducing effects of opioid agonists, including their priming strength in reinstatement studies and their impact in brain regions known to be involved in drug-induced reinforcement in MRI studies. Here we directly address this issue by investigating the effects of continuous exposure to naltrexone on 1) fentanyl-induced reinstatement of drug-seeking behavior, 2) fentanyl-induced patterns of blood oxygenation level dependent (BOLD) activation in the nucleus accumbens (NAcc), and 3) fentanyl-induced changes in NAcc functional connectivity (FC) in awake non-human primates that are engaged in ongoing opioid self-administration studies. We found that naltrexone antagonizes the priming strength of fentanyl as shown by a rightward shift in its reinstatement dose-effect curve and that naltrexone surmountably antagonizes the BOLD response induced by fentanyl. However, while naltrexone also countered fentanyl's effects on NAcc FC, the effects were not surmounted by a higher dose of fentanyl. Together, these data suggest that, in contrast to naltrexone's modulation of fentanyl's effects on behavior and BOLD responses, their interactive effects on FC between multiple brain regions do not reflect their receptor-mediated activity. Additionally, we demonstrated opposing effects in the absence and presence of naltrexone on NAcc FC at baseline (i.e., in the absence of any fentanyl prime) suggesting that naltrexone alters FC at baseline, even though naltrexone appears behaviorally silent in the absence of an agonist prime. Together these data provide additional insight into ways in which naltrexone interacts with opioid agonists, both behaviorally and in the brain. Further understanding the effects of opioid agonists on patterns of FC could help elucidate our understanding of the neural processes that contribute to the initiation of and relapse to opioid-seeking behavior in OUD.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: